Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx IncfiledCriticalModernatx Inc
Publication of AR108761A1publicationCriticalpatent/AR108761A1/en
La divulgación se refiere a moléculas de ARN modificadas que codifican polipéptidos de VEGF-A y a formulaciones que comprenden el ARN modificado. Los aspectos de la divulgación se refieren además a preparaciones y a usos de formulaciones que comprenden el ARN modificado para tratar a sujetos que padecen enfermedades sensibles a la terapia con VEGF-A.The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and to formulations comprising the modified RNA. Aspects of the disclosure also relate to preparations and uses of formulations comprising modified RNA to treat subjects suffering from diseases sensitive to VEGF-A therapy.
ARP170101533A2016-06-072017-06-05
MODIFIED RNA CODIFYING ENDOTELIAL GROWTH FACTOR POLYPEPTIDES A (VEGF-A), FORMULATIONS AND USES RELATED TO THE SAME
AR108761A1
(en)
fusion protein of an antibody, polynucleotide, vector, host cell, pharmaceutical composition, methods for producing a fusion protein and treating a disease in an individual and use of the fusion protein
Tumor associated peptide; nucleic acid; expression vector; recombinant host cell; method for producing the peptide; activated t lymphocytes and their production method; antibody; tcr; use to treat cancer; kit and pharmaceutical composition; method for producing vaccine; and Aptary (divisional application no. 201702407).